What Should Happen After a Dezawa Muse Stem Cell Injection?

Most of the attention in regenerative medicine falls on the treatment itself. The decision to pursue therapy. The consultation. The injection. And then, for many patients, a period of uncertainty — because no one has clearly explained what comes next.

At STEMS Health in Miami Beach, Drs. Ankeet Choxi and Jarred Mait treat that post-procedure period as a clinical phase in its own right. What happens in the weeks and months following a Dezawa Muse stem cell injection is not a passive waiting period. It is an active phase of biological activity — one that is shaped by patient behavior, clinical oversight, and the structure of follow-up care.

Understanding the timeline begins with a foundational concept: the injection is the beginning of the regenerative process, not its conclusion.

In the first week after a Muse cell injection, the biological focus is on the early tissue response. Some mild soreness, local swelling, or increased awareness of the injection area is normal and expected. It reflects the body's response to both the procedural intervention and the cellular activity beginning at the target site. This is not a sign that something has gone wrong. In most cases, it is a sign that the tissue is responding.

During this window, certain medications warrant particular attention. Systemic corticosteroids and specific anti-inflammatory agents can blunt the early regenerative response — the same response that Muse cell therapy is designed to initiate. At STEMS Health, patients receive specific guidance on which medications to avoid and for how long. They are also given clear parameters for what warrants a call to the practice: significant or worsening swelling beyond 72 hours, fever or systemic symptoms, new neurological findings, or any change that falls outside the expected pattern.

Weeks two through six represent what clinicians at STEMS Health describe as the early regenerative window. During this period, cell homing and early differentiation are most active. Many patients begin noticing incremental shifts — changes in pain levels, modest improvements in mobility or function, or simply a sense that something in the treated area is different. The progression is rarely linear. Some patients experience a temporary increase in awareness of the treatment area before improvement becomes consistent. That pattern is recognized and expected.

A structured clinical check-in during this window is not optional in the STEMS Health model. It is a deliberate assessment — an opportunity for the treating physicians to evaluate whether the response is tracking appropriately and whether any modification to the patient's activity protocol or rehabilitation guidance is warranted.

For most musculo-skeletal conditions, the primary improvement arc unfolds between weeks six and sixteen. This is the period when tissue remodeling and structural repair — stimulated by Muse cell activity — become measurable through both patient-reported outcomes and clinical examination. Patients who have followed activity guidance, maintained appropriate anti-inflammatory management, and stayed engaged with follow-up appointments during this window consistently demonstrate better outcomes than those who have not. Engagement during the regenerative window is not incidental to the result. It is part of the treatment.

For neurological conditions, complex degenerative presentations, or patients who received combination protocols, the relevant timeline extends further. Neurological regeneration is a slow, staged biological process. Progress may not be dramatic in the early months, and the absence of dramatic change should not be interpreted as treatment failure. At STEMS Health, longer-term follow-up is structured around the specific condition and clinical trajectory of each patient.

Every patient treated at STEMS Health receives a post-procedure care plan before leaving the practice. It is not a general handout. It is a personalized document built around the patient's specific condition, the procedure that was performed, and the recovery timeline appropriate to their clinical profile. Follow-up appointments are scheduled, not left to the patient to initiate. The physicians remain accessible between appointments for questions or concerns that arise outside the scheduled intervals.

Patients evaluating regenerative medicine providers should ask explicitly what the post-procedure protocol includes — how often they will be seen, what is being monitored, and how the practice responds if progress deviates from expected benchmarks. A provider whose post-procedure care is clearly defined and clinically structured is a provider whose commitment to the outcome extends beyond the procedure itself.

The regenerative process requires time, appropriate clinical conditions, and physician oversight that does not end when the needle is withdrawn. At STEMS Health, that oversight is designed into the treatment model — because the outcome of a Muse cell injection is shaped as much by what follows as by the injection itself.

To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.

-------------

As regenerative medicine continues to advance, more patients are hearing about Dezawa MuseCells® and their unique biological properties. At the same time, the growing popularity of this technology has created an important challenge: products being marketed as "MUSE cells" that are not authentic Dezawa MuseCells®.

In today's episode, we'll explain why authenticity matters, what questions patients should ask, and why scientific validation is more important than ever.

When an innovative medical technology gains attention, it's common for similar products to enter the marketplace. Regenerative medicine is no exception.

As awareness of Dezawa MuseCells® has increased, so has the number of products using the term "MUSE." However, the name alone does not guarantee authenticity.

According to scientists involved with the development and study of the technology, if a product was not generated using Professor Mari Dezawa's validated derivation and characterization protocols, it should not be considered an authentic Dezawa MuseCell®.

That distinction isn't about marketing.

It's about scientific validation.

Authentic Dezawa MuseCells® have been investigated through decades of laboratory research, preclinical studies, and clinical experience. Their biological characteristics have been documented using validated manufacturing methods and rigorous quality standards.

One of the most remarkable characteristics described in the scientific literature is their ability to naturally home to damaged tissue.

Unlike many other cellular products, authentic Dezawa MuseCells® respond to signals released by injured tissue and migrate to those locations without external guidance.

This unique biological behavior is one of the reasons they continue to generate significant interest within the field of regenerative medicine.

However, these characteristics cannot simply be assumed because another product carries a similar name.

The defining properties associated with authentic Dezawa MuseCells® result from specific derivation, characterization, validation, and manufacturing processes.

Without those validated methods, there is no scientific basis to conclude that another product possesses the same biological profile or safety characteristics.

This is why patients should never hesitate to ask questions before receiving any regenerative medicine treatment.

Ask whether the product being used is an authentic Dezawa MuseCell®.

Ask whether it was generated using Professor Mari Dezawa's validated protocol.

Ask whether the manufacturer can document the product's origin and quality standards.

And ask what published scientific evidence supports the specific cellular product being offered.

These are reasonable questions, and reputable providers should welcome them.

Another important development is that patients no longer need to travel internationally to access authentic Dezawa MuseCells®.

They are now available in the United States through MuseCell® Innovations licensed manufacturers, providing physicians with access to products produced under validated manufacturing standards.

As interest in regenerative medicine continues to grow, education remains one of the most valuable tools patients have.

Similar names do not necessarily represent similar science.

A logo can be copied.

A product name can be copied.

Scientific validation cannot.

Understanding that distinction can help patients make more informed decisions and have more meaningful conversations with their healthcare providers.

Thank you for listening to The Miami Stem Cell Podcast, presented by STEMS Health.

To learn more about regenerative medicine and authentic Dezawa MuseCells®, visit STEMS Health for additional educational resources.

This podcast is provided for informational and educational purposes only and should not be considered medical advice. Individual treatment decisions should always be made in consultation with a qualified healthcare professional.

To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.

-------------

What Actually Determines Success in Dezawa Muse Stem Cell Therapy?

There is a gap in how regenerative medicine is often evaluated — by patients, by the industry, and sometimes by providers themselves. The conversation centers on what can be measured at the lab level: cell counts, processing standards, product certifications. These are visible. They are quantifiable. They are easy to compare.

They are also, by themselves, remarkably poor predictors of whether a patient actually improves.

At STEMS Health in Miami Beach, Drs. Ankeet Choxi and Jarred Mait have identified three factors that consistently differentiate patients who achieve meaningful outcomes from those who do not. None of them are lab metrics. All of them are clinical.

The first is diagnostic precision.

Dezawa Muse stem cells are not a broad-spectrum treatment for pain or degeneration. They are a targeted biological intervention with specific mechanisms — stress-guided homing, tissue-specific differentiation, immunomodulation. That targeting only works when the tissue being treated is correctly identified. A patient presenting with knee pain might have osteoarthritis, meniscal pathology, periarticular bursitis, or some combination. These are different conditions with different structural implications. Treating the wrong pathology — or treating the right pathology with an imprecise understanding of its extent — produces results that fall short of what the therapy is capable of.

At STEMS Health, every protocol begins with a confirmed diagnosis. Imaging. Clinical correlation. Laboratory workup. The protocol is designed around that diagnosis — not around a symptom description or a generalized complaint.

The second factor is injection technique.

Even a well-characterized, high-potency Muse cell preparation achieves very little if it is not delivered accurately to the target tissue. Injection technique is a procedural skill that encompasses approach angle, imaging guidance, depth calibration, and the prevention of cellular leakage into non-target tissue. At STEMS Health, musculo-skeletal injections are performed under ultrasound guidance — real-time visualization that confirms the cells are deposited precisely at the intended site, whether that is within a joint capsule, a tendon sheath, a disc space, or a neural structure.

That precision is not incidental to the therapy. It is the mechanism by which the cells reach the tissue that needs them. Without it, even a superior preparation becomes a clinical approximation.

The third factor is post-procedure follow-up care.

The injection is not the conclusion of treatment. It is the beginning of a biological process that unfolds over days, weeks, and months. Muse cells initiate cellular homing, differentiation, and tissue remodeling across an extended regenerative window. The clinical environment during that window directly influences how well those processes develop.

Patients who receive an injection and then disengage from structured care consistently underperform compared to patients who remain engaged. At STEMS Health, follow-up is not a courtesy — it is a clinical protocol. Scheduled reassessments allow the treating physicians to monitor functional progress, adjust rehabilitation guidance, manage the anti-inflammatory environment appropriately, and identify early signals that warrant attention. Imaging follow-up is conducted when indicated to assess structural changes at the treatment site.

Taken together, these three factors tell a consistent story. The lab produces the tool. The physician determines whether that tool reaches its target, in the right patient, with the right diagnosis, delivered with precision, and supported through the recovery window with clinical intent.

When evaluating a regenerative medicine provider, patients are best served by asking not about lab credentials — but about the diagnostic process, the injection guidance protocol, and the structure of follow-up care. Those answers will reveal far more about the likely outcome than any comparison of cell counts or facility certifications.

At STEMS Health, the sequence is consistent across every patient: diagnose with precision, design the protocol around that diagnosis, deliver with imaging guidance, and follow up with clinical purpose. That sequence is not a differentiator. It is the standard.

To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.

-------------

If you've been looking into regenerative medicine, you've probably run into two terms a lot. Mesenchymal stem cells, or MSCs, and Dezawa MUSEcells. Your first question is probably the obvious one. Which one should I actually get?

At STEMS Health, Drs. Ankeet Choxi and Jarred Mait get this question constantly. The honest answer is, it depends on your biology, your condition, and the dose required to get the job done.

MSCs work through paracrine signaling. They release bioactive molecules that calm inflammation and support tissue repair across a broad area. They're not precise, but they're powerful when you need a wide, systemic effect.

Dezawa MUSEcells are different. They're a distinct pluripotent cell population discovered by Dr. Mari Dezawa, and their defining trait is precision. They self-direct toward damaged tissue, responding to the body's own distress signals, and differentiate once they get there. Think of MSCs as a wide net, and MUSEcells as cells that already know where they're going.

Here's where patients are usually surprised. A typical MSC protocol might use around fifty million cells. A Dezawa MUSEcells protocol often uses somewhere between ten and twenty five million. That's not because MUSEcells are a lesser therapy. It's because they work differently. Since they home directly to the site that needs them, you need fewer cells to get a comparable, or even better, result.

That's also where the value conversation comes in. As an MSC dose climbs higher, the cost climbs with it. At a certain point, a much smaller dose of Dezawa MUSEcells becomes more efficient and more cost effective. That's not a sales discount. It's just what happens when you need far fewer cells to do the same work.

That said, MUSEcells aren't automatically the better choice for everyone. Some conditions call for the broad effect a higher volume MSC protocol provides. Others are better served by the targeted, lower dose approach.

So how do you know which one is right for you? That comes down to a structured evaluation, looking at your inflammatory baseline, your imaging at the treatment site, and your prior treatment history. That evaluation, not a default package, determines whether MSCs, Dezawa MUSEcells, or a specific dose of either, is the right fit.

One more thing worth mentioning. Exosomes, tiny vesicles released by MSCs, are still part of the toolkit and may come up in your evaluation. But for most patients today, the real decision point is MSCs versus MUSEcells, with dose as the key variable.

If you're trying to figure out where you fall in that comparison, the next step is a real evaluation with Drs. Choxi and Mait, not a guess based on a podcast. Reach out to STEMS Health to find out which path fits your biology.

Disclaimer

The information provided in this podcast episode is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.

Certain regenerative medicine procedures discussed – such as stem cell therapy, exosome therapy, or other biologic treatments – may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.

Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.

© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.

To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.

-------------

Does More Dezawa Muse Stem Cells Mean Better Results?

In regenerative medicine, numbers move people. Cell counts appear in marketing materials, comparison charts, and patient forums. The assumption behind them is intuitive: more cells delivered to a damaged tissue should mean a stronger regenerative signal, a faster recovery, a better outcome.

At STEMS Health in Miami Beach, Drs. Ankeet Choxi and Jarred Mait encounter this assumption constantly. And their clinical experience points to a different conclusion.

Cell count is a data point. It is not a clinical outcome.

What determines whether a Dezawa Muse stem cell preparation actually performs is not how many cells are in the vial. It is whether those cells are potent, whether they are viable, and whether they are being administered with physician-guided precision to a correctly identified target.

Potency refers to a cell's functional capacity. Can it recognize and home to damaged tissue? Can it differentiate into the appropriate cell type once it arrives? Can it modulate the immune environment in a way that supports healing rather than triggering resistance? These are biological capabilities — not quantities. A preparation with a lower cell count but high potency, confirmed through strong SSEA-3 expression and robust differentiation markers, will outperform a high-volume, low-potency preparation in virtually every clinical scenario.

Viability refers to how many of those cells are alive and metabolically active at the moment of injection. Cells lose viability during handling, transport, and storage. A preparation marketed at a high cell count may arrive at the injection site with a fraction of those cells actually capable of therapeutic activity. Dead cells produce no regenerative signal. They do not differentiate. They do not modulate. They simply occupy space in a protocol that the patient paid for and trusted.

This is why the sourcing environment, processing standards, and delivery timing of a Muse cell preparation carry clinical weight. At STEMS Health, lab data on each preparation is reviewed before administration. Viability percentage, SSEA-3 positivity, differentiation capacity — these are not background details. They are part of the clinical decision.

There is also a risk that runs counter to the more-is-better assumption. Introducing an excessive volume of biological material into the body without calibration to the patient's immune status, inflammatory baseline, and injury profile can trigger unintended inflammatory cascades. The goal of a regenerative protocol is not to maximize cell volume. It is to deliver cells that are fit to perform, in a quantity appropriate to the patient's individual biology, at a site that has been confirmed through diagnostic precision.

At STEMS Health, every Muse cell protocol begins with a structured pre-treatment evaluation. The diagnosis is confirmed through imaging and clinical correlation. The patient's immune and inflammatory baseline is assessed. The preparation is reviewed for quality markers. The injection site is evaluated for anatomical targeting. Only when that evaluation is complete does the protocol take shape.

That process cannot be replaced by a higher number on a marketing sheet. It requires a physician who understands what they are treating, why they are treating it, and what quality of biological material is being delivered into a body that is depending on that judgment.

When patients evaluate regenerative medicine providers, the most important questions are not about volume. They are about potency, viability, diagnostic process, and physician-guided protocol design. Those are the variables that determine what happens after treatment. And at STEMS Health, those are the variables that guide every decision made before it.

This is STEMS Health — regenerative medicine in Miami Beach, guided by clinical precision.

To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.

-------------

Today we’re breaking down a term that comes up in regenerative medicine, but isn’t always clearly explained—stem cell passage.

If you’ve been researching treatments, you’ve probably seen numbers tied to cell counts. Millions of cells, sometimes more. But what’s often missing from that conversation is how those cells were grown before they were used.

That’s where passage comes in.

At its simplest, stem cell passage refers to how many times cells have been grown and re-cultured in a lab. It starts with an initial population—what’s often called passage zero. As those cells divide and multiply, they eventually need more space. So they’re split, transferred into new environments, and allowed to grow again.

Each time that cycle happens, the passage number increases.

So when someone refers to early passage or late passage cells, they’re talking about how many rounds of expansion those cells have gone through.

Now, this process—called in vitro expansion—is what allows labs to take a relatively small starting sample and grow it into a much larger number of cells. From a production standpoint, it’s efficient. It makes treatments more scalable.

But there’s another side to it.

As cells continue to divide, they don’t just increase in number—they also begin to change.

Early passage cells tend to behave more like they did in their original environment. They may be more responsive to signals, more adaptable, and more consistent in how they function.

As passage number increases, cells can gradually shift. Their signaling behavior may change. Their ability to adapt to new environments may become less predictable. Over time, they may begin to reflect the lab conditions they were grown in, rather than the tissue they came from.

This doesn’t happen all at once. And it doesn’t mean later passage cells don’t work. But it does introduce a variable.

So now you have a balance.

On one side, you have quantity. More passages mean more cells. On the other side, you have functional characteristics—how those cells behave once they’re used.

And that leads to a common question: is more always better?

The answer depends on what the treatment is trying to do.

If the goal is primarily signaling—helping influence inflammation or communicate with surrounding tissue—then higher passage cells may still play a meaningful role.

But if the goal involves more direct interaction with tissue—responding to damage, adapting to a specific environment, or participating in longer-term repair—then the characteristics of the cells may matter more than the total number.

This is especially relevant in targeted treatments, like joint or spine procedures, where cells are placed precisely into a specific area. In those cases, how the cells behave locally can be more important than how many are delivered overall.

Another important distinction is between viability and potency.

Viability refers to how many cells are alive. Potency refers to what those cells are capable of doing. You can have a high number of viable cells, but if their functional characteristics have shifted over time, their behavior may be different than earlier passage cells.

So again, it’s not just about the number—it’s about the profile.

One reason passage isn’t always discussed is because it’s more complex than a single metric. It doesn’t give you a simple comparison point like total cell count. Instead, it’s part of a bigger picture that includes how the cells were sourced, how they were processed, and how they’re being used.

But understanding it adds an important layer of context.

Because in regenerative medicine, how something is made can influence how it works.

So the takeaway here is simple: stem cell passage is a measure of how cells are expanded in the lab. As passage increases, so does quantity—but the cells may also undergo gradual changes that affect how they behave.

And when you’re evaluating treatment options, that balance between expansion and function is worth understanding.

Disclaimer

The information provided in this podcast episode is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.

Certain regenerative medicine procedures discussed – such as stem cell therapy, exosome therapy, or other biologic treatments – may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.

Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.

© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.

To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.

-------------

Today we’re addressing a question that comes up often in regenerative medicine conversations: why can’t we get certain stem cell treatments here in the United States?

If you’ve done any research, you’ve probably seen clinics in other countries offering therapies that don’t seem to be available domestically. On the surface, that can feel confusing. It may even raise the question—are we behind?

The reality is more structured than that. In the U.S., access to stem cell therapies is shaped by regulation—specifically, oversight from the U.S. Food and Drug Administration.

The FDA is responsible for evaluating biologic treatments, including cell-based therapies, to determine whether they are safe, consistent, and effective for patient use. And the way they do that is by applying a defined framework.

At the center of that framework are a few key ideas.

One is minimal manipulation—how much the cells have been altered outside the body. The more a therapy changes the structure or function of those cells, the more regulatory oversight it requires.

Another is homologous use—whether the cells are being used in a way that matches their original function. If they’re used for something different, that typically places the therapy into a more regulated category.

These distinctions may sound technical, but they directly determine what can be offered in a clinical setting and what requires further approval.

So when a treatment isn’t available in the U.S., it’s often because it hasn’t yet moved through the full regulatory process.

That process usually begins with what’s called an investigational pathway, where therapies are studied in controlled environments. From there, they move through multiple phases of clinical trials—each one designed to evaluate safety, dosing, and effectiveness.

And this is where time becomes a factor.

Even promising therapies can take years to complete this process. Not because they don’t work, but because they haven’t yet generated the level of data required for broad approval.

Another layer to this is standardization.

Biologic therapies are complex. They involve living or biologically derived materials, which means consistency matters. The FDA requires adherence to manufacturing standards that ensure each treatment is produced under controlled conditions and behaves predictably.

That’s part of what’s known as good manufacturing practice.

These requirements help reduce variability and improve safety, but they also add complexity to development and approval.

In other countries, regulatory systems may operate differently. Some allow therapies to reach patients more quickly, often with different thresholds for data and oversight.

That can make treatments appear more accessible internationally. But availability doesn’t always mean the same level of evaluation or consistency.

So rather than thinking of it as a gap, it’s more accurate to see it as a difference in how systems approach risk, data, and patient protection.

It’s also important to note that regenerative medicine is not absent in the U.S.

Certain therapies are available within defined regulatory boundaries, and others can be accessed through clinical trials or limited pathways designed for investigational treatments.

So the landscape isn’t closed—it’s structured.

And that structure reflects a balance between two things: innovation and oversight.

Regenerative medicine is advancing quickly. New therapies are being developed all the time. But bringing those therapies into widespread use requires a process that evaluates how they perform—not just in theory, but across real patient populations.

For patients, the takeaway is this: when a treatment isn’t available in the U.S., it doesn’t necessarily mean it lacks potential. More often, it means it’s still moving through a system designed to understand it more fully.

And asking the right questions—about regulatory status, clinical data, and how a therapy is being evaluated—can provide a clearer picture than availability alone.

Disclaimer

The information provided in this podcast episode is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.

Certain regenerative medicine procedures discussed – such as stem cell therapy, exosome therapy, or other biologic treatments – may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.

Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.

© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.

To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.

-------------

Today we’re talking about something that doesn’t always get the attention it deserves in regenerative medicine—follow-up care. Specifically, what to look for after Muse stem cell therapy, and how to recognize when follow-up may not be structured the way it should be.

When most people think about treatment, they focus on the procedure itself. The cells, the injection, the day of the visit. But with regenerative therapies, that’s only one part of the process.

What happens after the procedure is where outcomes begin to take shape.

MUSE cell therapy works over time. The body responds gradually through processes like cell signaling, immune modulation, and tissue adaptation. That means results don’t show up all at once, and they don’t always follow a straight line.

Because of that, follow-up care becomes part of the treatment—not just something that happens after it.

So what does it look like when follow-up isn’t quite where it should be?

One of the first signs is when communication feels unstructured. There’s no clear schedule for check-ins, no guidance on when updates should happen, and patients are left to reach out only when something feels off.

In that kind of environment, it becomes harder to understand what’s normal and what isn’t. Subtle improvements might go unnoticed, and temporary discomfort might feel more concerning than it actually is.

Another common issue is when recovery guidance is too general.

After treatment, patients are often told to “take it easy” or “listen to your body.” While that sounds reasonable, it doesn’t provide much direction. Regenerative therapies usually require a balance—some level of movement to support function, but also enough protection to allow tissue to adapt.

Without clear guidance, patients are left to guess. And that can influence how well the treatment integrates over time.

There’s also the question of how progress is being tracked.

If follow-up is based only on general conversation—how are you feeling, any changes—it can be difficult to measure what’s actually happening. Without a baseline or consistent reference points, even meaningful improvements can be hard to quantify.

Structured follow-up doesn’t have to be complicated, but it should create a way to see patterns over time.

Another thing to pay attention to is whether follow-up feels individualized.

Regenerative medicine is built around the idea that each patient responds differently. But if every patient is placed on the same timeline, with the same expectations, that can suggest a more standardized approach.

Some patients need closer monitoring early on. Others may need more time between check-ins. A thoughtful follow-up plan adjusts to that.

And then there’s the bigger picture—how the treatment fits into everything else.

MUSE cell therapy is often part of a broader strategy that might include physical therapy, movement work, or other supportive care. If follow-up doesn’t connect those pieces, the treatment can start to feel isolated.

When care is integrated, each part supports the other. When it’s not, progress can become less predictable.

Finally, there’s expectation setting.

Regenerative therapies don’t always follow a predictable timeline. Improvement can be gradual. Sometimes there are periods where things feel unchanged, or even temporarily more noticeable before they improve.

If that’s not explained ahead of time, it can lead to uncertainty. Patients may question whether the treatment is working, when in reality they may be within a normal phase of response.

So what does strong follow-up look like?

It’s clear, structured, and responsive. There’s a plan for communication. There’s guidance for recovery. There’s a way to track progress. And there’s flexibility to adjust based on how the body responds.

And importantly, it creates a partnership. The provider brings clinical perspective, and the patient brings real-world feedback. Together, that builds a more complete picture of how treatment is unfolding.

The key takeaway here is simple: in MUSE stem cell therapy, the procedure is only one part of the process. Follow-up is where that treatment is observed, understood, and supported over time.

And when follow-up is done well, it helps bring clarity to a process that is, by nature, gradual and evolving.

Disclaimer

The information provided in this podcast episode is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.

Certain regenerative medicine procedures discussed – such as stem cell therapy, exosome therapy, or other biologic treatments – may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.

Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.

© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.

To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.

-------------

Today we’re taking a closer look at a topic that doesn’t usually come up in patient consultations, but plays a meaningful role in how regenerative treatments are developed and priced. That’s the concept of cell passage—and how increasing cell passages can reduce costs, while also influencing how cells behave.

If you’ve explored regenerative therapies, you’ve likely heard numbers tied to treatment. Fifty million cells. One hundred million cells. Sometimes more. Those numbers can feel like a clear indicator of strength or effectiveness.

But what’s often not discussed is how those cells were expanded before they were ever used.

Cell passage refers to the number of times cells have been grown and re-cultured in a laboratory environment. It starts with an initial population—what’s often called passage zero. As those cells multiply, they’re divided and transferred into new culture environments. That becomes passage one. Then passage two. And the process continues.

Each passage increases the total number of cells. And from a production standpoint, this is where cost efficiency begins to take shape.

Because the more times cells are expanded, the more volume a lab can generate from a single starting sample. That means more doses can be produced without needing additional source material. Over time, this reduces the cost per unit, and allows treatments to be offered at different price points.

So when you see higher cell counts associated with a therapy, part of what you’re seeing is the result of this expansion process.

But there’s another side to it.

As cells go through repeated passages, they don’t just increase in number—they also experience gradual biological changes. These changes aren’t abrupt, and they don’t render cells ineffective, but they can influence how those cells respond once introduced into the body.

Over time, cells in culture may become less responsive to signaling cues. Their ability to adapt to a new environment may shift. Their overall behavior can begin to reflect the lab conditions they’ve been grown in, rather than the original tissue they came from.

This creates a balance that isn’t always visible in treatment discussions.

On one hand, higher passage expansion allows for greater volume and lower cost. On the other, earlier passage cells may retain characteristics that are closer to their original biological state.

So the question becomes less about how many cells are being delivered, and more about how those cells are expected to function.

Different treatment goals place different demands on cell behavior.

In some cases, the primary objective is signaling—helping to influence inflammation or communicate with surrounding tissue. In those scenarios, higher passage cells may still contribute meaningfully.

In other cases, the goal involves more direct interaction with tissue. This might include responding to localized damage, adapting to a specific environment, or participating in longer-term repair processes. In those contexts, the functional characteristics of the cells can become more relevant than the total number alone.

This is especially true in joint, spine, and musculo-skeletal applications, where treatments are often delivered with a high degree of precision.

In many of these procedures, image-guided techniques such as ultrasound or fluoroscopy are used to place cells directly into the area of concern. When delivery is highly targeted, the behavior of the cells at that specific location becomes a central part of the treatment design.

That level of precision can shift the conversation even further away from volume, and toward how cells respond once they’re in place.

It’s also worth noting that cell passage is not typically highlighted in patient-facing materials. Most discussions focus on metrics that are easier to communicate—like total cell count. While those numbers provide a reference point, they don’t capture how the cells were expanded or how many passages they’ve undergone.

And that’s where some of the confusion in the market comes from.

Two treatments may present similar cell counts, but the underlying production methods—and therefore the biological profiles—may differ.

This doesn’t mean that one approach is automatically better than another. It means that production methods influence how cells behave, and that behavior should align with the goals of the treatment.

From a broader perspective, increasing cell passages is a practical solution for scaling regenerative therapies. It allows laboratories to operate efficiently, maintain supply, and manage costs in a way that supports wider access.

At the same time, it introduces variables that are worth understanding—especially for patients comparing options.

The takeaway here is not that higher passage is good or bad. It’s that cell passage is part of the biological story, not just a manufacturing detail.

When evaluating a treatment, it can be helpful to look beyond the headline numbers and consider how the therapy is designed. What is it trying to accomplish? How are the cells expected to behave? And how does the production process support that goal?

In regenerative medicine, those questions often matter more than the total count alone.

Ultimately, effective treatment planning is less about maximizing inputs and more about matching the right biologic approach to the right condition.

Disclaimer

The information provided in this podcast episode is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.

Certain regenerative medicine procedures discussed – such as stem cell therapy, exosome therapy, or other biologic treatments – may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.

Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.

© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.

To learn more about regenerative and restorative stem cell therapy treatments, visit www.stemshealthregenerativemedicine.com or schedule a consultation at our Miami Beach clinic, located at 925 W 41st St #300A, Miami Beach, FL 33140, You can also reach us by phone at (305) 677.0565.

-------------

Today we’re digging into a question that’s coming up more often in regenerative medicine conversations: Do you need exosomes if you’re already getting MUSE stem cells?

On the surface, this can sound like a simple add-on decision. But when you step into the biology behind it, the answer becomes more about mechanism than menu options.

Let’s start by grounding the difference.

MUSE cells—short for multilineage-differentiating stress-enduring cells—are a specific subset of mysynchemal stem cells. What makes them distinct is their ability to survive in difficult environments, respond to tissue damage, and integrate into the body in a controlled way. They don’t just signal repair—they participate in it.

Exosomes, on the other hand, are not cells. They’re microscopic vesicles released by cells. You can think of them as carriers of information. They move proteins, RNA, and signaling molecules from one cell to another, influencing how nearby cells behave.

So right away, we’re talking about two different levels of biology. One is a living system. The other is a communication tool used by that system.

Here’s where things start to overlap—and where confusion tends to happen.

MUSE cells naturally produce exosomes.

That’s a key point.

When MUSE cells are introduced into a treatment area, they don’t just sit there. They respond to the environment. They release signaling molecules. And part of that process includes generating exosomes in real time, based on what the tissue actually needs.

So when someone asks, “Should I add exosomes to my MUSE cell treatment?” the first layer of the answer is this: you’re already getting exosome activity as part of the cellular function.

That raises a logical follow-up question—when would additional exosomes actually matter?

There are scenarios where exosomes can play a supportive role. Not as a replacement, but as a kind of amplifier or primer.

For example, if the tissue environment is highly inflamed, or if healing capacity is compromised, exosomes may help shift that environment before or during treatment. They can influence inflammation, support signaling pathways, and potentially make the area more receptive to cellular activity.

In that sense, exosomes can be used to prepare the ground.

There are also cases where timing becomes important.

If exosomes are used before a procedure, they may help modulate inflammation and improve the local environment. If they’re used during the procedure, they can provide immediate signaling support alongside the cells. And if they’re used after, they may help reinforce ongoing repair processes.

But none of that means they are always necessary.

In many localized treatments—especially when MUSE cells are delivered precisely into a joint or a specific tissue structure—the cells themselves are already doing multiple jobs. They’re responding to damage, adapting to the environment, and producing signaling molecules as needed.

In those cases, adding exosomes may not significantly change the outcome.

And this is where the conversation shifts from products to protocols.

One of the more common issues in regenerative medicine right now is the tendency to bundle therapies together without clearly explaining the role each one plays. More inputs don’t automatically lead to better results. What matters is alignment between the therapy and the condition.

MUSE cells and exosomes are not interchangeable. And they’re not automatically additive.

They operate in the same ecosystem, but they serve different roles within it.

MUSE cells are active participants in repair. Exosomes are part of the communication network that supports that repair.

So the real question isn’t, “Should I get both?” It’s, “What does my specific condition require, and how do these tools fit into that?”

Another factor that often gets overlooked is how the treatment is delivered.

In many MUSE cell protocols, especially for orthopedic or spine-related issues, image guidance is used to place the cells directly into the area of concern. That level of precision can reduce the need for broader systemic signaling support.

If the cells are exactly where they need to be, and the environment supports their function, they may be able to carry out their role without additional inputs.

On the other hand, in less targeted or more systemic conditions, exosomes may have a different kind of value.

So again, context is everything.

What this really points to is a larger shift in how we think about regenerative medicine.

It’s not about choosing between options on a list. It’s about understanding how different biologic tools behave—and how they interact within the body.

MUSE cells represent a dynamic, adaptive approach. Exosomes represent a signaling-based approach. Sometimes those approaches overlap in useful ways. Sometimes they don’t need to.

And that distinction matters.

Because when treatment decisions are based on mechanism rather than marketing, the conversation becomes a lot more precise.

So if you’re evaluating these options, the takeaway is straightforward: MUSE cells already produce exosomes as part of their function. In some cases, adding exosomes may support the process. In others, it may not add meaningful value.

The right approach depends on the condition, the environment, and the goals of treatment.

Disclaimer

The information provided in this podcast episode is for educational and informational purposes only and is not intended as medical advice. Treatments and outcomes described may not be appropriate for every individual. Always consult a licensed healthcare provider to determine the best course of care for your specific needs.

Certain regenerative medicine procedures discussed – such as stem cell therapy, exosome therapy, or other biologic treatments – may be considered investigational or not FDA-approved for all conditions. Florida law requires that we disclose this status. While these procedures are offered in accordance with state and federal guidelines, their safety and efficacy have not been fully established by the U.S. Food and Drug Administration.

Results vary, and no guarantee of specific outcome or benefit is implied. All medical procedures involve potential risks, which should be discussed with your treating provider prior to treatment.

© STEMS Health Regenerative Medicine, Miami Beach, Florida. All rights reserved.